Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On Travere Therapeut

Travere Therapeutics’ shares surged more than 13% in after-hours trading after the company reported results that beat expectations. For the period ended June 30, Travere posted total revenue of $169.58 million, topping analyst estimates of $159.32 million by 6.44%. U.S. net product sales rose to $161.4 million from $94.8 million a year earlier. Sales of its flagship drug, FILSPARI, reached $141.1 million, up 96% year over year. On earnings, the company reported an EPS loss of $0.10, worse than the analyst estimate of a $0.23 loss, and net loss widened to $34.8 million from $12.8 million, including a $40 million charge tied to 2029 convertible note repurchases. TVTX closed Tuesday at $56.02.